SA
Go ProLog In
DSGN
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
7 analysts·Limited coverage
64
Score
4 Buy (57%)3 Hold (43%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
457%
Hold
343%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$14.00
+30.8%
Consensus
$17.50
+63.6%
Bull
$21.00
+96.3%
12-Month Target Range7 analysts
$14.00$17.50$21.00
Current $10.70Consensus
Current Price
$10.70
Upside to Consensus
$6.80

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+74.53%
EPS—
FY2028
Rev-96.58%
EPS—
FY2029
Rev+807.03%
EPS—

Earnings Surprises

Recent Analyst Actions

May 4, 2026Oppenheimer
Design Therapeutics price target raised to $21 from $18 at Oppenheimer
Target:$21.00
+57.9%from $13.30
Apr 29, 2026Piper Sandler
Design Therapeutics price target raised to $20 from $12 at Piper Sandler
Target:$20.00
+31.2%from $15.24
Jan 7, 2026Oppenheimer
Design Therapeutics initiated with an Outperform at Oppenheimer
Target:$18.00
+104.1%from $8.82
Dec 3, 2025Craig-Hallum
Design Therapeutics initiated with a Buy at Craig-Hallum
Target:$15.00
+67.8%from $8.94
Dec 3, 2025Leerink Partners
Design Therapeutics upgraded to Outperform from Market Perform at Leerink
Target:$14.00
+56.6%from $8.94
May 7, 2024Piper Sandler
Piper Sandler Upgrades Design Therapeutics Inc (DSGN) to Overweight
Target:$12.00
+228.8%from $3.65
Aug 15, 2023RBC Capital
Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments
Target:$7.00
+223.3%from $2.17
Dec 7, 2022Piper Sandler
Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler
Target:$42.00
+231.0%from $12.69
May 2, 2022RBC Capital
RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30
Target:$30.00
+151.3%from $11.94
Jan 19, 2022Goldman Sachs
Design Therapeutics Stock (DSGN): $10 Price Target From Goldman Sachs
Target:$10.00
-28.5%from $13.98

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance